Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $299.4 million.

  • Immunome's Liabilities and Shareholders Equity rose 1653.54% to $299.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 1538.99%. This contributed to the annual value of $240.2 million for FY2024, which is 6173.49% up from last year.
  • Latest data reveals that Immunome reported Liabilities and Shareholders Equity of $299.4 million as of Q3 2025, which was up 1653.54% from $296.3 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Liabilities and Shareholders Equity ranged from a high of $342.7 million in Q1 2025 and a low of $41.4 million during Q2 2023
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $256.9 million (2024), whereas its average is $216.6 million.
  • In the last 5 years, Immunome's Liabilities and Shareholders Equity surged by 61489.08% in 2024 and then rose by 2.53% in 2025.
  • Immunome's Liabilities and Shareholders Equity (Quarter) stood at $148.5 million in 2023, then skyrocketed by 61.73% to $240.2 million in 2024, then grew by 24.62% to $299.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $299.4 million for Q3 2025, versus $296.3 million for Q2 2025 and $342.7 million for Q1 2025.